F8 and hemophilia A: The 2nd DPT of the CWA-APTT (routine APTT) showed a convex decrease in the mixing test with normal and FVIII-deficient plasma and a straight line in the mixing test with normal and FVIII-deficient plasma containing emicizumab and with plasma from a hemophilia A patient with an inhibitor treated with emicizumab and FVIII-deficient plasma (Figure 4a).